People in the News

Tempus AI has announced the formation of its advisory board of medical professionals:

• David Carbone, a professor of medical oncology and director of the James Thoracic Oncology Center at the Ohio State University Medical Center.
• Babar Bashir, an associate professor in the department of medical oncology in the division of solid tumors at Thomas Jefferson University.
• Amy Cummings, an assistant professor in the division of hematology/oncology at the University of California, Los Angeles.
• Tapan Kadia, a professor in the department of leukemia at the University of Texas MD Anderson Cancer Center who also serves as co-leader of the sections of AML and developmental therapeutics.
• Marc Matrana, an endowed professor and system director of precision medicine at Ochsner MD Anderson Cancer Center.
• Robert McWilliams, a consultant and professor of oncology at Mayo Clinic and the deputy director of the cancer practice at the Mayo Clinic Comprehensive Cancer Center.
• Tara Mitchell, section chief of melanoma and sarcoma in hematology oncology and an associate professor of medicine at the Hospital of the University of Pennsylvania.
• Nicholas Mitsiades, professor of medicine and associate director for translational research at the UC Davis Comprehensive Cancer Center.
• Ben Park, director of the Vanderbilt-Ingram Cancer Center and a professor of medicine in the division of hematology and oncology at Vanderbilt University.
• B. J. Rimel, an associate professor of obstetrics and gynecology at Cedars-Sinai and the medical director of the Cancer Clinical Trials Office at Cedars-Sinai Cancer.
• Mothaffar Rimawi, executive medical director of the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine.
• Assuntina Sacco, professor of internal medicine in the division of hematology-oncology and co-director of the Hanna and Mark Gleiberman Head and Neck Center of Excellence at UC San Diego Health Moores Cancer Center.
• Alexander Spira, codirector of the Virginia Cancer Specialists Research Institute and CEO and director of NEXT Oncology Virginia.

Two of Biodesix's board members, Charles Watts, and Jack Schuler, have notified the company that they will resign at the conclusion of the company's planned annual meeting, scheduled for May 20. Watts has served as a director of the company since July 2019. Biodesix stated that his resignation is not due to any disagreement with the company on any matter relating to its operations, policies, or practices.

Schuler, currently director of the board and a member of the nominating and corporate governance committee, has held his position as director since 2008. With his exit, he will transition to the role of director emeritus, where he will continue to provide his expertise and guidance to Biodesix in a non-voting, advisory capacity. As with Watts, Biodesix said that Schuler's resignation is not due to any mutual disagreement.

Clare Murray has been appointed as CEO of enzymatic RNA synthesis company EnPlusOne. Most recently, she was senior VP of corporate development and operations at Life Edit Therapeutics, a company she cofounded. She was also head of business development and strategy at ElevateBio, which acquired Life Edit. Previously, she held senior roles at AgBiome, Aptuit, Scynexis, and Novartis. Murray holds a BSc in chemistry and a PhD in synthetic organic chemistry from the University of Liverpool and an MBA from Fuqua School of Business at Duke University.

Ferran Prat has been appointed as chief commercial officer of molecular and immune profiling company BostonGene. He joins the firm from the University of Texas MD Anderson Cancer Center, where he was VP of research administration and industry relations. Prior to that, he held various leadership positions at Alere and its predecessors, now part of Abbott Laboratories. Prat holds a PhD in organic chemistry from the University of California Los Angeles and a JD from the University of San Diego School of Law.

CellBio, a Palo Alto, California-based provider of biomedical research tools and services, has appointed Charles Miller as CEO. Miller has more than 15 years of leadership experience in drug discovery and diagnostics, including at organizations such as the Jackson Laboratory and Elephas Biosciences. He holds a BS and PhD in biomedical sciences from the University of Michigan and Michigan State University, and an MBA from Yale University.

Cancer early detection company Freenome has appointed Aaron Elliott as CEO. Elliott most recently served as CEO and president of Realm IDx, overseeing its subsidiaries Ambry Genetics, Invicro, and Konica Minolta Realm-Japan. He was also CEO of Ambry Genetics from 2016 to 2021 and led the $1 billion acquisition of Ambry by Konica Minolta in 2017 (Ambry was subsequently acquired by Tempus AI in February 2025). He joined Ambry in 2008 as an R&D scientist and later became its CSO. Elliot did his PhD training in genetics at the Sidney Kimmel Cancer Center at Thomas Jefferson University and Johns Hopkins University School of Medicine, and he holds a BS in biology from Franklin & Marshall College.

John Sperzel, Robin Toft, John Cumming, David Elsbree, Seymour Liebman, and Laura Adams have resigned from the board of directors of T2 Biosystems, following the firm's recent demise. Michael Gibbs, Sperzel, and John Sprague also resigned from their executive positions with the company and terminated their consulting agreements with the firm. Sperzel previously served as CEO and president of T2 Biosystems, while Gibbs served as senior VP, general counsel, and corporate secretary. Sprague was the company's CFO and corporate treasurer. 

T2 has appointed Craig Jalbert as CEO, president, corporate treasurer, corporate secretary, and as a class I director. He will also serve as the company's principal executive officer, principal financial officer, and principal accounting officer. Jalbert is a principal of Massachusetts-based accounting firm Verdolino and Lowey and focuses on distressed businesses, serving as officer and director for companies in their wind-down phases.

Myriad Genetics has appointed Brian Donnelly as its new chief commercial officer, effective May 1. Donnelly previously held senior commercial and general management roles at Ancestry, Amazon, and Illumina.

Hologic has expanded its board of directors from eight to nine directors and appointed Wayde McMillan to the open position, effective April 4. The company also appointed him to its audit and finance committee. McMillan is the CFO of healthcare firm Solventum, a carve-out company that was formed from 3M's healthcare business, and he previously served in executive roles for medical device firms Insulet, Medtronic, and Covidien.

Agilent Technologies said that Heidi Kunz is resigning from the company's board of directors as well as the firm's compensation committee and nominating and corporate governance committee, effective May 21. She is a former executive VP and CFO for Blue Shield of California.